---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-004166"
form_type: "8-K"
ticker: "MTVA"
cik: "0001638287"
company_name: "MetaVia Inc."
filed_at: "2024-03-28T23:59:59+00:00"
generated_at: "2026-06-04T06:13:30.983403+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# NeuroBo reports FY 2023 net loss $12.5M; cash $22.4M; DA-1726 Phase 1 to dose Q2 2024

## Summary
- Net loss $12.5M ($2.46 per share) vs $14.0M in FY 2022; R&D spend rose to $9.2M.
- Cash $22.4M as of Dec. 31, 2023, expected to fund operations into Q4 2024.
- DA-1726 Phase 1 obesity trial: first site IRB approved; first patient dosing expected Q2 2024.
- DA-1241 Phase 2a MASH trial: SRC approval to continue; full data expected H2 2024.
- Marshall Woodworth appointed permanent CFO; company regained Nasdaq compliance after reverse split.

## SEC filing metadata
- accession: 0001558370-24-004166
- form_type: 8-K
- ticker: MTVA
- cik: 0001638287
- company_name: MetaVia Inc.
- filed_at: 2024-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638287/000155837024004166/0001558370-24-004166-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638287/000155837024004166/nrbo-20240328x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-004166
- JSON: https://secwatch.observer/filing/0001558370-24-004166.json
- Plain text: https://secwatch.observer/filing/0001558370-24-004166.txt

## Key facts
- Earnings Releases
  MetaVia Inc. reported financial results for the year ended December 31, 2023.
  - Period: the year ended December 31, 2023
  - Result: reported results
  source text: NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the year ended December 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1638287/000155837024004166/0001558370-24-004166-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.